Tag:
Pfizer
Latest Headlines
Latest Headlines
Pfizer lays out MRSA vaccine battle plan
Reuters has looked inside the Pfizer lab tasked with developing a vaccine for the drug-resistant superbug MRSA.
Pfizer offers share exchange to grant Zoetis its freedom
Pfizer is cutting the apron strings at Zoetis. Just months after its highly successful IPO, in which Pfizer sold off a 20% stake, the animal health business is set to become fully independent. Pfizer is offering a stock swap to its shareholders, who can exchange $100 in Pfizer shares for roughly $107 worth of Zoetis stock.
Does pharma spend more on marketing than R&D? A numbers check
So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.
Pfizer's effort to confront shortage leads to second Levoxyl recall
Pfizer began recalling its thyroid drug Levoxyl this year after getting complaints of odors from the bottles tied to a new formulation, a move that threatened to lead to a shortage of the drug. So its King Pharmaceuticals subsidiary returned to making the older formulation. But now it has to recall 84 lots of that product because there appears to be potency issues.
Pfizer points to pandemic potential of Prevnar 13
In pandemic flu preparation, a lot of focus is placed on protecting against the specific viral strain. Yet analysis of the 1918 pandemic shows secondary bacterial pneumonia directly caused many of the deaths. This brings Pfizer's Prevnar 13 into play, and the Big Pharma is talking up its role.
Pfizer picks up the pieces after its armed antibody crashes in PhIII
Pfizer says inotuzumab failed a Phase III study for aggressive CD22+ non-Hodgkin's lymphoma. The monitoring committee concluded that inotuzumab in combination with rituximab was not going to deliver the data needed on overall survival.
Pfizer-backed analysis finds dearth of patient-reported outcomes in trials
An analysis of online data found that only 7.4% of 650 clinical trials for diabetes treatments included patient-reported outcomes, which are supposed to shed light on patients' experiences on the meds.
JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets
Joint ventures with Chinese companies have been seen as a way for Big Pharma to get better traction in the exploding China market. But it is not a one-way street. Chinese companies see the tie-ups as a way to build their own capabilities and begin to tap lucrative Western markets.
Mined doctor-patient data gives drugmakers insight for targeted marketing
The recent layoffs of hundreds of drug sales reps mean there are fewer people in the field calling on doctors to see what they are prescribing. But they don't have to--drugmakers have found new tools that actually can tell them more about doctors' prescribing patterns than the physicians even know themselves.
Pfizer to close Ireland plant by next year
An active pharmaceutical ingredient facility in Cork County, Ireland, has been targeted for closure next year, although Pfizer hopes its can save the 136 jobs there by selling it to another drugmaker.
